| Protein Name |
Glutathione Synthetase |
| Gene |
[GSS](/genes/gss) |
| UniProt |
P16455 |
| PDB ID |
1GSA, 1GSH, 2GSS |
| Molecular Weight |
52 kDa (474 amino acids) |
| Subunit Structure |
Homodimer (2 × 52 kDa) |
| Localization |
Cytosol, mitochondria |
| Protein Family |
ATP-grasp fold family |
| Brain Expression |
High in hippocampus, cortex, cerebellum |
Glutathione Synthetase (GSS) is the second and final enzyme in the biosynthesis of glutathione (GSH), the most abundant cellular antioxidant. GSS catalyzes the ATP-dependent conversion of γ-glutamylcysteine and glycine to form glutathione, completing the two-step biosynthesis pathway that begins with glutamate-cysteine ligase (GCL, also known as γ-glutamylcysteine synthetase).
Glutathione is the critical tripeptide (γ-glutamyl-cysteinyl-glycine) that serves as:
- The primary cellular antioxidant
- A detoxifying agent for xenobiotics and heavy metals
- A regulator of redox signaling
- A cofactor for various enzymes
GSS deficiency leads to severe metabolic and neurological consequences, demonstrating the essential nature of this enzyme. In neurodegenerative diseases, GSS function is often compromised, contributing to oxidative stress and disease progression.
GSS is a homodimeric enzyme with the following structural features:
Each Subunit Contains:
- N-terminal domain: Involved in γ-glutamylcysteine binding
- Central ATP-grasp domain: The catalytic core
- C-terminal domain: Contains glycine-binding site
GSS uses an ATP-dependent mechanism:
- ATP binding to the enzyme's active site
- Activation of γ-glutamylcysteine through phosphorylation
- Glycine addition forming the peptide bond
- Release of glutathione and ADP
The reaction:
γ-Glutamylcysteine + Glycine + ATP → Glutathione + ADP + Pi
- Walker A motif (P-loop) for ATP binding
- Mg²⁺ requirement for catalysis
- Substrate tunnel for sequential binding
- Dimer interface required for activity
GSS plays the final step in GSH synthesis:
Step 1: GCL (glutamate-cysteine ligase)
Glutamate + Cysteine + ATP → γ-Glutamylcysteine + ADP + Pi
Step 2: GSS (glutathione synthetase)
γ-Glutamylcysteine + Glycine + ATP → Glutathione + ADP + Pi
Antioxidant Defense:
- Directly scavenges reactive oxygen species (ROS)
- Regenerates other antioxidants (vitamin C, vitamin E)
- Serves as substrate for glutathione peroxidase
Detoxification:
- Conjugates xenobiotics for excretion
- Protects against heavy metals (mercury, lead, cadmium)
- Neutralizes electrophilic compounds
Redox Signaling:
- Maintains thiol redox balance
- Modulates protein function through S-glutathionylation
- Regulates transcription factor activity
In neurons and glia:
- Protects against excitotoxicity
- Maintains mitochondrial function
- Supports neurotransmitter synthesis
- Enables astrocyte-neuron glutathione shuttle
GSS dysfunction is strongly implicated in PD pathogenesis:
Evidence:
- GSS activity reduced in substantia nigra of PD patients
- Glutathione levels severely depleted in PD brain
- GSS polymorphisms associated with PD risk
Mechanisms:
- Dopaminergic vulnerability: GSH protects dopaminergic neurons from oxidative damage
- Mitochondrial dysfunction: GSH deficiency impairs complex I function
- α-Synuclein aggregation: Oxidative stress promotes misfolding
The PD GSH Depletion Cascade:
Environmental toxins → Oxidative stress → GSH depletion
↓
GSS dysfunction → Impaired GSH synthesis → Neuronal vulnerability
↓
Dopaminergic neuron loss → Motor symptoms → Parkinson's disease
GSS involvement in AD:
Findings:
- Reduced GSS activity in AD hippocampus
- Decreased GSH levels in AD brain
- GSS gene variants may influence AD risk
Mechanisms:
- Amyloid toxicity: Aβ induces oxidative stress that depletes GSH
- Tau pathology: Hyperphosphorylated tau associated with GSH depletion
- Synaptic dysfunction: GSH loss impairs synaptic plasticity
- Neuroinflammation: Activated glia consume GSH
Evidence:
- GSH levels reduced in ALS spinal cord
- GSS activity decreased in motor neurons
- Oxidative stress markers elevated
Connections:
- SOD1 mutations: Cause oxidative stress requiring GSH buffering
- Energy failure: Mitochondrial dysfunction increases ROS
- Excitotoxicity: Glutamate-induced oxidative stress
- Huntington's Disease: GSH depletion in striatum
- Multiple Sclerosis: Demyelination associated with GSH deficiency
- Friedreich's Ataxia: Frataxin deficiency impairs GSH metabolism
| Partner |
Interaction |
Function |
| GCL (GCLC/GCLM) |
Sequential pathway |
First step of GSH synthesis |
| Glutathione peroxidase |
Substrate provider |
ROS detoxification |
| Glutathione reductase |
Regeneration |
Maintains reduced GSH |
| γ-Glutamyl transpeptidase |
GSH metabolism |
Extracellular GSH processing |
| Glutathione S-transferases |
Substrate |
Xenobiotic detoxification |
| Approach |
Mechanism |
Status |
| Gene therapy |
Increase GSS expression |
Preclinical |
| Small molecule activators |
Direct GSS activation |
Research |
| GSH precursors |
Increase substrate availability |
Clinical |
| N-acetylcysteine |
Cysteine delivery |
Clinical trials |
| GSH analogs |
Antioxidant replacement |
Research |
Parkinson's Disease:
- N-acetylcysteine (NAC) supplementation: Ongoing trials
- GSH infusion: Some clinical benefit reported
- GSS gene therapy: Preclinical validation
Alzheimer's Disease:
- NAC in combination therapy: Phase II trials
- GSH prodrugs: Research stage
ALS:
- GSH modulation: Multiple trials
- Antioxidant approaches: Limited efficacy
- Blood-brain barrier limits delivery
- GSH has poor cellular uptake
- Redox balance must be maintained
- Timing of intervention critical
GSS deficiency is a rare autosomal recessive disorder:
Clinical Features:
- 5-oxoprolinuria (elevated 5-oxoproline in urine)
- Metabolic acidosis
- Hemolytic anemia
- Neurological symptoms (developmental delay, seizures, ataxia)
Treatment:
- Sodium bicarbonate for acidosis
- Antioxidant supplementation
- Avoidance of oxidative stress
- Gene therapy (experimental)
- Glutathione metabolism in neurodegeneration (2015)
- Glutathione synthetase in brain disorders (2018)
- Glutathione and antioxidant therapy in neurodegenerative disease (2012)
- Glutathione synthetase deficiency and neurological disease (2019)